CPHA Canvax

"Antibody-dependent enhancement (ADE) occurs when antibodies are unable to neutralize a virus’ infectivity, but instead enhance a virus’ ability to infect cells. Although ADE has been observed in humans who received the dengue vaccine, as well as in individuals that received a vaccine candidate for the respiratory syncytial virus, the evidence from COVID-19 vaccine clinical trials so far have not shown more severe disease occurring in vaccinated participants. People who have been given the COVID-19 vaccine will continue to be closely monitored to determine whether ADE occurs." - No evidence that COVID-19 vaccines cause more severe disease; antibody-dependent enhancement has not been observed in clinical trials

Rating See Comments Ratings


Vaccine Safety and Development,Research and Development,Vaccine Technology and New Vaccines,Vaccination Decision Making,Sub Topics: Vaccination Decision Making,Misinformation/Disinformation,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19 Vaccine Safety and Development
Research and Development
Vaccine Technology and New Vaccines
Vaccination Decision Making
Sub Topics: Vaccination Decision Making
Monitoring and Surveillance
Outbreaks and Pandemics


Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.

All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.